ACTON, Mass., Feb. 27, 2017 /PRNewswire/ -- Bluejay Diagnostics, Inc. (Bluejay) today announced a collaborative clinical research agreement with Hitachi Chemical Co., Ltd. (Hitachi Chemical) to develop a non-invasive, point-of-care test that measures total IgE in human tears. The technology could be used to aid in the diagnosis of Allergic Conjunctivitis, i.e. "Pink Eye." Under this collaboration, Hitachi Chemical will provide its technology, knowledge and understanding of the product to perform clinical trials and regulatory applications in the United States, Europe and South America.
"Strengthening the allergy business is part of Hitachi Chemical's in vitro Diagnostics strategy. Our collaboration in developing a point of care total tear IgE test with Bluejay and expansion into non-invasive in vitro diagnostics is right in line with this strategy," said, Tsuyoshi Uchida, Director of Medical Business Unit of Hitachi Chemical. "With the tear IgE test in the US market, it will complement our flagship OPTIGEN® (allergen-specific IgE assay) product line and expand our US allergy business."
According to Svetlana Dey, President and CEO of Bluejay, "Our collaboration with Hitachi Chemical in developing a total tear IgE non-invasive test complements Bluejay's research and development strategy of tailored point-of-care diagnostics, or in other words, finding the right material and technology at the right time for patients. Through our collaboration with Hitachi Chemical, we hope to deliver non-invasive, rapid, point-of-care tests that enhance patient care and just as importantly avoid unnecessary treatment regimens, such as antibiotics."
The agreement will provide Bluejay with access to Hitachi Chemical's Allerwatch™ product - currently marketed in Japan for diagnosis of Allergic Conjunctivitis - for exclusive development, marketing and manufacturing in North America, South America and Europe.
About Hitachi Chemical Co., Ltd.
Hitachi Chemical Co., Ltd. (Tokyo Stock Exchange：4217), headquartered in Tokyo, Japan, delivers wide range of innovative products, such as electronic materials, automobile parts, energy storage devices and systems, in global markets. The company's consolidated revenues for fiscal 2015 (ended March 31, 2016) totaled 547 billion yen ($4.8 billion). For more information on Hitachi Chemical, please visit the company's website at http://www.hitachi-chem.co.jp/english/.
About Bluejay Diagnostics, Inc.
Bluejay Diagnostics, Inc., headquartered in Acton, Massachusetts, develops, manufactures and markets non-invasive, point-of-care (POC) tests that provide patients and providers access to affordable and timely healthcare in markets with unmet needs. The company's flagship product, a POC test for Allergic Conjunctivitis, is currently undergoing U.S. FDA 510(k) clinical trials with an expected launch in late 2017.
Contact: Jeffrey Aidt
Senior Director, Corporate Marketing
Tel: 978 631 4870
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bluejay-diagnostics-inc-announces-clinical-research-collaboration-to-develop-point-of-care-test-for-allergic-conjunctivitis-300412809.html
SOURCE Bluejay Diagnostics, Inc.